BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

The employee options carry a $3.31 exercise price and vest over time, subject to continued service.

Rhea-AI Summary

BridgeBio Oncology Therapeutics (NASDAQ: BBOT) awarded stock options covering 90,000 shares on October 10, 2026, to induce a new employee’s employment.

The employee was hired in September 2026. The non-qualified options have an exercise price of $3.31 per share, matching the closing price on the last trading day before the grant’s effective date. One-quarter vests on the first anniversary of the employee’s applicable start date, with the remainder vesting in 36 equal monthly installments, subject to continued service. The compensation committee approved the award under the 2025 Inducement Plan, outside stockholder-approved equity incentive plans, in accordance with Nasdaq Listing Rule 5635(c)(4).

Positive

• None.

Negative

• Minor point. Forward-looking: it has not happened yet and may not happen.Options covering 90,000 shares at $3.31 per share create potential dilution if exercised.

Key Figures

Options granted: 90,000 shares Exercise price: $3.31 per share Vesting schedule: 1/4 on the first anniversary, then 36 equal monthly installments

Options granted

90,000 shares

Inducement award to one employee

Exercise price

$3.31 per share

Equal to the closing price on the last trading day before the grant's effective date

Vesting schedule

1/4 on the first anniversary, then 36 equal monthly installments

Subject to continued service through each vesting date

Historical Context

1 past event · Latest: Aug 11

1 event

1. Aug 11

   Inducement grant

   24h Move

   +2.4%

   Prior grant under the same plan covered two hires: 65,350 options at $9.28 per share.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

non-qualified stock options, nasdaq listing rule 5635(c)(4)

2 terms

non-qualified stock options financial

"The employee received non-qualified stock options to purchase an aggregate 90,000 shares"

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced it awarded an inducement grant on October 10, 2026, under BBOT’s 2025 Inducement Plan as a material inducement to the employment of one individual hired by BBOT in September 2026.

The employee received non-qualified stock options to purchase an aggregate 90,000 shares of BBOT common stock, par value $0.0001 per share, with an exercise price of $3.31 per share, the closing price of BBOT’s common stock as reported by Nasdaq on the last trading day prior to the effective date of the grant, which will vest 1/4 on the first anniversary of the employee’s applicable start date and in 36 equal monthly installments thereafter, subject to the employee’s continued service with the Company through each applicable vesting date, or collectively, the Awards.

All of the above-described Awards were granted outside of BBOT’s stockholder-approved equity incentive plans and are pursuant to BBOT’s 2025 Inducement Plan, which was adopted by BBOT’s board of directors in October 2025. The Awards were approved by the compensation committee of the board of directors, which is comprised solely of independent directors, as a material inducement to the employees entering into employment with BBOT in accordance with Nasdaq Listing Rule 5635(c)(4).

About BBOT
BBOT is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies. BBOT has the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors. For more information, please visit www.bbotx.com and follow us on LinkedIn.

BBOT Contacts:

Investor Contact:
BBOT
Investors@BBOTx.com

Media Contact:
Jake Robison
Inizio Evoke Comms
Jake.robison@inizioevoke.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many inducement stock options did BBOT award, and at what exercise price?

BBOT awarded one employee non-qualified stock options to purchase 90,000 shares at an exercise price of $3.31 per share. The award was granted on October 10, 2026, to an employee hired in September 2026.

When do BBOT’s October 2026 inducement options vest?

One-quarter of the options vests on the first anniversary of the employee’s applicable start date, followed by 36 equal monthly installments. Vesting is subject to the employee’s continued service through each applicable vesting date.